{"id":"treatment-experienced-patients-lndl-therapy","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Without access to detailed pharmacological data on this specific formulation from the National Liver Institute, Egypt, the exact mechanism cannot be definitively stated. LNDL may refer to a combination therapy or a proprietary treatment protocol. Further clinical documentation would be required to specify the precise molecular targets and mechanism of action.","oneSentence":"LNDL therapy is a treatment regimen for treatment-experienced patients, likely involving antiviral or immunomodulatory mechanisms for liver disease management.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:14:11.406Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-experienced liver disease patients (specific indication not clearly defined)"}]},"trialDetails":[{"nctId":"NCT05184491","phase":"PHASE4","title":"Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management","status":"UNKNOWN","sponsor":"National Liver Institute, Egypt","startDate":"2021-10-15","conditions":"Helicobacter Pylori","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Treatment-experienced patients- LNDL therapy","genericName":"Treatment-experienced patients- LNDL therapy","companyName":"National Liver Institute, Egypt","companyId":"national-liver-institute-egypt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LNDL therapy is a treatment regimen for treatment-experienced patients, likely involving antiviral or immunomodulatory mechanisms for liver disease management. Used for Treatment-experienced liver disease patients (specific indication not clearly defined).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}